Stockscreener 앱 받기
127.68
1.93%
-2.51
전일 마감가:
$130.19
열려 있는:
$130
하루 거래량:
1.19M
Relative Volume:
1.06
시가총액:
$12.84B
수익:
$2.86B
순이익/손실:
$478.60M
주가수익비율:
27.35
EPS:
4.6676
순현금흐름:
$748.70M
1주 성능:
-4.18%
1개월 성능:
-0.14%
6개월 성능:
-11.33%
1년 성능:
+20.73%
1일 변동 폭
$127.20
$130.34
1주일 범위
$127.20
$134.11
52주 변동 폭
$104.42
$160.18
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
127.68 | 12.84B | 2.86B | 478.60M | 748.70M | 4.6676 |
TAK
Takeda Pharmaceutical Co Adr
|
16.63 | 52.54B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.87 | 49.15B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.58 | 42.62B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.64 | 35.68B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
567.16 | 24.86B | 3.18B | 1.33B | 1.04B | 27.90 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Neurocrine-Soleno deal garners Wall Street praise — analyst applauds business development acumen - MSN
Neurocrine nears $2.5B-plus deal to buy Soleno TherapeuticsFT - MSN
CRENESSITY Phase 3 Data on Lower Steroid Doses Could Be A Game Changer For Neurocrine Biosciences (NBIX) - simplywall.st
Neurocrine to buy Soleno Therapeutics for $53/share in cash - MSN
Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN
Neurocrine Biosciences (NASDAQ:NBIX) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
Morgan Stanley Maintains Neurocrine Biosciences (NBIX) Overweight Recommendation - MSN
Ruffer LLP Invests $2.48 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Deutetrabenazine Market to Witness Massive Growth by 2033 |Teva - openPR.com
Neurocrine reports sustained glucocorticoid reductions in CAH study By Investing.com - Investing.com India
Zurcher Kantonalbank Zurich Cantonalbank Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine reports sustained dose reductions with CRENESSITY in CAH patients - StreetInsider
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia - ChartMill
NBIX Maintained by Leerink Partners -- Price Target Raised to $1 - GuruFocus
How Neurocrine Biosciences Inc. (NBIX) Affects Rotational Strategy Timing - Stock Traders Daily
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $170.00 - MarketBeat
Belpointe Asset Management LLC Acquires Shares of 9,485 Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Why this Bay Area company took a buyout offer that was nearly $2 billion less than an earlier bid - The Business Journals
3 Reasons Growth Investors Will Love Neurocrine (NBIX) - Yahoo Finance
Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Maintains Target Price $185 - Moomoo
Wall Street Analysts Think Neurocrine (NBIX) Could Surge 38.79%: Read This Before Placing a Bet - Yahoo Finance
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
Lobbying Update: $940,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed - Quiver Quantitative
Neurocrine is making a $2.9 billion bet on a new kind of drug - MSN
Neurocrine Biosciences (NASDAQ: SLNO) offers $53.00 per share cash to Soleno - Stock Titan
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Unveiling a 39.92% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
KBC Group NV Has $4.60 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
NBIX SEC FilingsNeurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Persistence Data And Options Activity - simplywall.st
Cwm LLC Purchases 11,306 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
A Look at Neurocrine Biosciences Inc (NBIX) After 3.8% Gain -- G - GuruFocus
Neurocrine's Acquisition Impacts Soleno Therapeutics (SLNO) Rati - GuruFocus
How New Real-World INGREZZA Data Versus AUSTEDO XR Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st
Neurocrine Biosciences (NASDAQ:NBIX) Rating Increased to Hold at Zacks Research - MarketBeat
Sumitomo Mitsui Trust Group Inc. Decreases Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Massachusetts Financial Services Co. MA Sells 10,415 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Q3 2025 Earnings Preview - MSN
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with a Bullish Technical Setup - ChartMill
Neurocrine Expands CNS Pipeline With Nxera Schizophrenia Trial And Milestones - Sahm
How Investors May Respond To Neurocrine Biosciences (NBIX) INGREZZA Real-World Persistence Edge Over AUSTEDO XR - Yahoo Finance
Is It Time To Reassess Neurocrine Biosciences (NBIX) After Its Recent Share Price Pullback? - Yahoo Finance
Real World INGREZZA Data May Support Neurocrine’s Tardive Dyskinesia Lead - Sahm
Neurocrine Biosciences | DEF 14A: Definitive information statements - Moomoo
Form DEFA14A NEUROCRINE BIOSCIENCES - StreetInsider
Neurocrine Biosciences (NBIX) seeks approval for 4M-share equity plan boost - Stock Titan
Is the Options Market Predicting a Spike in Neurocrine Biosciences Stock? - Zacks Investment Research
Neurocrine Biosciences identifies new CRF2 receptor agonists - BioWorld News
Robeco Institutional Asset Management B.V. Purchases 85,076 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking - MSN
Neurocrine Biosciences Inc (NBIX) Stock Up 3.6% and Still Undervalued -- GF Score: 96/100 - GuruFocus
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.90%
0.66%
자본화:
|
볼륨(24시간):